TIL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TIL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Instil Bio's Trailing 12-Month Free Cash Flow is $-58.58 Mil, and Market Cap is $143.37 Mil. Therefore, Instil Bio's FCF Yield % for today is -40.86%.
The historical rank and industry rank for Instil Bio's FCF Yield % or its related term are showing as below:
During the past 5 years, the highest FCF Yield % of Instil Bio was -2.40%. The lowest was -328.88%. And the median was -78.67%.
Instil Bio's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.
The historical data trend for Instil Bio's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
FCF Yield % | - | - | -8.15 | -323.07 | -207.21 |
Instil Bio Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
FCF Yield % | Get a 7-Day Free Trial | -140.71 | -108.47 | -81.96 | -63.43 | -18.33 |
For the Biotechnology subindustry, Instil Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Instil Bio's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Instil Bio's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Instil Bio's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -102.692 | / | 49.5597942 | |
= | -207.21% |
Instil Bio's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -20.133 | * | 4 | / | 439.2811764 | |
= | -18.33% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Instil Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy L. Moore | officer: Chief Operating Officer | C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404 |
Sumita Ray | officer: Chief Legal and Admin Officer | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Nimish P Shah | director | 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018 |
Jack Nielsen | director, 10 percent owner | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Mcgaughy R Kent Jr | director | 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201 |
Curative Ventures V Llc | 10 percent owner | 3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219 |
Bronson Crouch | director, 10 percent owner, officer: CEO and Chairman | C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
Vivo Capital Ix, Llc | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Sandeep Laumas | officer: CFO and CBO | 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
Neil W Gibson | director | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
Gwendolyn Binder | director | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Zachary Roberts | officer: Chief Medical Officer | C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
George Matcham | director | C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
Vijay Chiruvolu | officer: Chief Technical Officer | C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 01-31-2023
By Business Wire Business Wire • 11-01-2022
By sperokesalga sperokesalga • 05-11-2023
By Tiesvg Tiesvg • 12-30-2022
By Marketwired • 08-13-2024
By Marketwired • 05-10-2024
By GuruFocus Research • 02-09-2024
By Value_Insider Value_Insider • 11-07-2022
By Business Wire Business Wire • 11-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.